Pro-IL-1β accumulation in macrophages by alendronate and its prevention by clodronate

Toxicology Letters

Volumn 199, Issue 2, 2010, Pages 123-128

  Shikama, Yosuke ^a,b   Nagai, Yasuhiro ^a   Okada, Satoru ^a   Oizumi, Takefumi ^a   Shimauchi, Hidetoshi ^a   Sugawara, Shunji ^a   Endo, Yasuo ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bisphosphonates; Interleukin 1beta; Macrophages

Indexed keywords

ALENDRONIC ACID; CLODRONIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; PRO INTERLEUKIN 1BETA; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; INTERLEUKIN 1; INTERLEUKIN 1 PRECURSOR; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; TOXICITY;

ALENDRONATE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CASPASE 1; CELL LINE; CLODRONIC ACID; INTERLEUKIN-1; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; PROTEIN PRECURSORS;

MURINAE; MUS;

EID: 77957943332     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.08.013     Document Type: Article

References (30)

1. Adami S., Bhalla A.K., Dorizzi R., Montesanti F., Rosini S., Salvagno G., Lo Cascio V. The acute-phase response after bisphosphonate administration. Calcif. Tissue Int. 1987, 41:326-331.
2. Austyn J.M., Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur. J. Immunol. 1981, 11:805-815.
3. Deng X., Yu Z., Funayama H., Shoji N., Sasano T., Iwakura Y., Sugawara S., Endo Y. Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate. Toxicol. Appl. Pharmacol. 2006, 213:64-73.
4. Deng X., Yu Z., Funayama H., Yamaguchi K., Sasano T., Sugawara S., Endo Y. Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: involvement of mevalonate pathway, TNFalpha, macrophages, and T-cells. Int. Immunopharmacol. 2007, 7:152-161.
5. Dinarello C.A. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am. J. Clin. Nutr. 2006, 83:447S-455S.
6. Drenth J.P., Cuisset L., Grateau G., Vasseur C., van de Velde-Visser S.D., de Jong J.G., Beckmann J.S., van der Meer J.W., Delpech M. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat. Genet. 1999, 22:178-181.
7. Endo Y., Shibazaki M., Yamaguchi K., Nakamura M., Kosugi H. Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Br. J. Pharmacol. 1999, 126:903-910.
8. Houten S.M., Kuis W., Duran M., de Koning T.J., van Royen-Kerkhof A., Romeijn G.J., Frenkel J., Dorland L., de Barse M.M., Huijbers W.A., Rijkers G.T., Waterham H.R., Wanders R.J., Poll-The B.T. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat. Genet. 1999, 22:175-177.
9. Lazarovici T.S., Yahalom R., Taicher S., Elad S., Hardan I., Yarom N. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J. Oral Maxillofac. Surg. 2009, 67:850-855.
10. Lipton A. Treatment of bone metastases and bone pain with bisphosphonates. Support Cancer Ther. 2007, 4:92-100.
11. Macarol V., Fraunfelder F.T. Pamidronate disodium and possible ocular adverse drug reactions. Am. J. Ophthalmol. 1994, 118:220-224.
12. Makkonen N., Salminen A., Rogers M.J., Frith J.C., Urtti A., Azhayeva E., Monkkonen J. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur. J. Pharm. Sci. 1999, 8:109-118.
13. Mandey S.H., Kuijk L.M., Frenkel J., Waterham H.R. A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum. 2006, 54:3690-3695.
14. Monkkonen H., Auriola S., Lehenkari P., Kellinsalmi M., Hassinen I.E., Vepsalainen J., Monkkonen J. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br. J. Pharmacol. 2006, 147:437-445.
15. Monkkonen H., Rogers M.J., Makkonen N., Niva S., Auriola S., Monkkonen J. The cellular uptake and metabolism of clodronate in RAW 264 macrophages. Pharm. Res. 2001, 18:1550-1555.
16. Monkkonen J., Koponen H.M., Ylitalo P. Comparison of the distribution of three bisphosphonates in mice. Pharmacol. Toxicol. 1990, 66:294-298.
17. Oizumi T., Yamaguchi K., Funayama H., Kuroishi T., Kawamura H., Sugawara S., Endo Y. Necrotic actions of nitrogen-containing bisphosphonates and their inhibition by clodronate, a non-nitrogen-containing bisphosphonate in mice: potential for utilization of clodronate as a combination drug with a nitrogen-containing bisphosphonate. Basic Clin. Pharmacol. Toxicol. 2009, 104:384-392.
18. Pelegrin P., Barroso-Gutierrez C., Surprenant A. P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J. Immunol. 2008, 180:7147-7157.
19. Roelofs A.J., Thompson K., Gordon S., Rogers M.J. Molecular mechanisms of action of bisphosphonates: current status. Clin. Cancer Res. 2006, 12:6222s-6230s.
20. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., Frith J.C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88:2961-2978.
21. Ruggiero S.L., Mehrotra B., Rosenberg T.J., Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 2004, 62:527-534.
22. Sauty A., Pecherstorfer M., Zimmer-Roth I., Fioroni P., Juillerat L., Markert M., Ludwig H., Leuenberger P., Burckhardt P., Thiebaud D. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 1996, 18:133-139.
23. Shikama, Y., Kuroishi, T., Nagai, Y., Iwakura, Y., Shimauchi, H., Takada, H., Sugawara, S., Endo, Y., Muramyldipeptide augments the actions of lipopolysaccharide in mice by stimulating macrophages to produce pro-IL-1B and by down-regulation of suppressor of cytokine signaling 1 (SOCS1). Innate Immun. doi:10.1177/1753425909347508.
24. Siris E.S. Bisphosphonates and iritis. Lancet 1993, 341:436-437.
25. Sugawara S., Shibazaki M., Takada H., Kosugi H., Endo Y. Contrasting effects of an aminobisphosphonate, a potent inhibitor of bone resorption, on lipopolysaccharide-induced production of interleukin-1 and tumour necrosis factor alpha in mice. Br. J. Pharmacol. 1998, 125:735-740.
26. Thiebaud D., Sauty A., Burckhardt P., Leuenberger P., Sitzler L., Green J.R., Kandra A., Zieschang J., Ibarra de Palacios P. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif. Tissue Int. 1997, 61:386-392.
27. Toyras A., Ollikainen J., Taskinen M., Monkkonen J. Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. Eur. J. Pharm. Sci. 2003, 19:223-230.
28. Van Rooijen N., Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J. Immunol. Methods 1994, 174:83-93.
29. Yamaguchi K., Motegi K., Iwakura Y., Endo Y. Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. Br. J. Pharmacol. 2000, 130:1646-1654.
30. Yamaguchi K., Yu Z., Kumamoto H., Sugawara Y., Kawamura H., Takada H., Yokochi T., Sugawara S., Endo Y. Involvement of Kupffer cells in lipopolysaccharide-induced rapid accumulation of platelets in the liver and the ensuing anaphylaxis-like shock in mice. Biochim. Biophys. Acta 2006, 1762:269-275.